E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
To evaluate the effect and tolerability of high dose Mg gluconate oral substitution in the (1) prevention and (2) treatment of magnesium wasting due to anti-EGFR treatment in colorectal cancer |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10005654 |
E.1.2 | Term | Blood magnesium decreased |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
• To evaluate the efficacy and tolerability of magnesium gluconate 3 g bid. given orally to modulate magnesium wasting in patients with colorectal cancer treated with EGFR targeted antibody therapy. • To evaluate the efficacy and tolerability of magnesium gluconate 3 g six times per day compared to 3 g bid. given orally to modulate magnesium wasting in patients with colorectal cancer with grade 2 hypomagnesemia induced by EGFR targeted antibody therapy
|
|
E.2.2 | Secondary objectives of the trial |
• To measure compliance to magnesium supplementation regimens • To measure the impact of magnesium supplementation on asthenia and Quality-of-Life
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Subjects with colorectal cancer in whom treatment with anti-EGFR targeted antibodies is being started in the metastatic or adjuvant setting. 2. Subjects must provide written witnessed informed consent prior to any study procedures being performed 3. Male or female subjects aged between 18 and 80 years 4. Subjects must be able to understand the study, comply with the study requirements and return to the investigational site for assessments at specified times
|
|
E.4 | Principal exclusion criteria |
1. Subjects treated with cisplatin based chemotherapy within 6 months prior to inclusion 2. Subjects with renal failure, i.e. creatinine levels > 2 mg/dl or creatinine clearance < 50 mg/dl 3. Subjects with baseline hypomagnesemia 4. Subjects with baseline diarrhea, i.e. > 4 bowel movements/day 5. Subjects with known intolerance to magnesium supplementation 6. Subjects with short bowel 7. Subjects with known or impending bowel obstruction
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
After informed consent has been given, subjects meeting the inclusion criteria will be randomised to two different therapeutic approaches:
• Arm A: No intervention (part 1), until appearance hypomagnesemia grade 1, followed by magnesium gluconate 3 g bid. orally (part 2) • Arm B: Prophylactic treatment with magnesium gluconate 3 g bid orally (part 1) until appearance of hypomagnesemia grade 1, followed by magnesium gluconate 3 g 6X/day orally (part 2) The primary efficacy variables of the part 1 of the study will be: • The slope of the change in serum magnesium levels since baseline • The mean number of bowel movements per day. The secondary efficacy variables of this part of the study will be: • The mean number of missed doses • The mean grade of fatigue according to CTC version 3.0 • The QoL score at two-weekly intervals recorded with the QLQ-C30 questionnaire from EORTC. • Patients will end part 1 of the study, as soon as the subjects have one serum magnesium level with grade 1 hypomagnesemia. They will then be entered in part 2.
The primary efficacy variables of part 2 of the study will be: • The slope of the change in serum magnesium levels since appearance of grade 1 hypomagnesaemia • The mean number of bowel movements per day. The secondary efficacy variables of this part of the study will be: • The mean number of missed doses • The mean grade of fatigue according to CTC version 3.0 • The QOL score at two-weekly intervals recorded with the QLQ-C30 questionnaire from EORTC. • |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
different dose of same product |
|
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 20 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 12 |
E.8.9.1 | In the Member State concerned days | |